Nitric Oxide Physiology and Redox Interactions
Nitric oxide (NO) is produced by three NOS isoforms: eNOS (endothelial, constitutive, Ca2+/calmodulin-regulated, produces picomolar NO for vasodilation); nNOS (neuronal, constitutive, synaptic plasticity, LTP); and iNOS (inducible, cytokine-driven, produces nanomolar-micromolar NO for cytotoxic antimicrobial defence). NO signalling operates through: (1) sGC activation → cGMP → PKG (vasodilation, platelet inhibition, neuroprotection); (2) S-nitrosylation of protein cysteine residues (post-translational redox regulation); (3) iron-nitrosyl formation in metalloenzymes; and (4) at high [NO]: peroxynitrite (ONOO−) formation with superoxide, causing nitrosative damage. The NO/superoxide ratio determines whether NO promotes health (vascular function, neuroprotection) or pathology (peroxynitrite-mediated protein nitration, DNA strand breaks).
Spirulina Mechanisms in NO Biology
eNOS Activation and Coupling
Spirulina AMPK→Akt eNOS Ser1177 phosphorylation (+20–35% NO) is detailed under vascular endothelium mechanisms. Additionally: spirulina AMPK increases L-arginine intracellular availability by upregulating cationic amino acid transporter 1 (CAT-1) expression in endothelial cells, ensuring substrate is not rate-limiting for eNOS. BH4 preservation (via Nrf2→GTPCH-I induction +15–20%) maintains eNOS in coupled state, producing NO rather than O2⋅−. Calmodulin activation: spirulina’s ability to normalise intracellular Ca2+ transients (via SERCA protection) provides adequate Ca2+/CaM for eNOS activation without Ca2+ overload.
iNOS Immunomodulation: Context-Dependent Regulation
iNOS expression is beneficial in acute infection contexts (cytotoxic NO production killing intracellular pathogens) but deleterious in chronic inflammation (sustained NO/ONOO− causing tissue damage). Spirulina phycocyanin NF-κB inhibition reduces cytokine-driven iNOS upregulation in macrophages, microglia, and hepatocytes under chronic inflammatory conditions (−25–40% iNOS mRNA in LPS/IFN-γ-stimulated cells). This reduces peroxynitrite formation in non-infectious contexts while preserving innate iNOS capacity during actual microbial challenge (spiral NF-κB inhibition is relative, not absolute). Net effect: lower nitrosative stress markers (3-nitrotyrosine −25–40%) without impaired infectious defence.
NO Bioavailability from Superoxide Competition
Superoxide (O2⋅−) reacts with NO at a diffusion-limited rate (k = 6–10×109 M−1;s−1;), competing with sGC for available NO. In cardiovascular disease, elevated NADPH oxidase-derived O2⋅− quenches eNOS-derived NO, producing peroxynitrite and reducing NO bioavailability despite normal eNOS activity. Spirulina SOD activity support (+15–25% CuZnSOD/MnSOD dismutating O2⋅− to H2O2, then catalase/GPx for H2O2 reduction) reduces the O2⋅− pool competing with NO. Result: greater fraction of eNOS-derived NO reaches sGC for cGMP production (+20–35% NOx/cGMP signalling output per unit eNOS activity).
cGMP–PKG Signalling Amplification
cGMP activates PKG1α/PKG1β in smooth muscle (causing relaxation via MLCK inhibition and Ca2+ channel phosphorylation), platelets (inhibiting activation), neurons (synaptic plasticity, CREB phosphorylation), and cardiomyocytes (anti-hypertrophic Regulator of calcineurin-1 upregulation). Spirulina antioxidants reduce PDE5/PDE1 oxidative inactivation (PDE enzymes hydrolyse cGMP — their inactivation prolongs cGMP signal), amplifying downstream PKG activity per NO pulse. This prolongs vasodilatory responses and platelet inhibition without requiring increased NO flux, effectively sensitising the cGMP-PKG pathway to existing NO signals.
Clinical Outcomes Related to NO Biology
- Serum NOx (nitrite/nitrate): +20–35%
- 3-Nitrotyrosine (peroxynitrite marker): −25–40%
- FMD (endothelial NO function): +1.5–3% absolute
- Systolic BP (NO-dependent): −4–8 mmHg
- iNOS in synovial fluid (RA/inflammatory joint): −25–40%
- Platelet aggregation (NO/cGMP-dependent): −15–25%
Dosing and Drug Interactions
Endothelial function/cardiovascular: 5–10g daily for 12–16 weeks. PDE5 inhibitors (sildenafil, tadalafil): Spirulina cGMP prolongation additive to PDE5 inhibitor effects; monitor hypotension. Organic nitrates (nitroglycerin): Spirulina BH4 preservation may partially prevent nitrate tolerance. L-arginine supplementation: Minimal additive benefit if dietary arginine adequate (eNOS is saturated; BH4/NADPH are rate-limiting). Summary: eNOS +20–35%, iNOS −25–40% (chronic inflammation), NOx +20–35%, 3-NT −25–40%, cGMP-PKG sensitisation; dosing 5–10g for 12–16 weeks. NK concern: low.